# Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

- Published: 2026-11-12
- Author: [Healthcare News](https://healthcarenews.io/author/healthcarenews-io.md)
- Topics: [News](https://healthcarenews.io/news.md)
- Source: https://healthcarenews.io/news/black-diamond-therapeutics-to-participate-in-upcoming-investor-conferences/
- Publication: Healthcare News
- Publisher: Connectively (Terkel, Inc.)
- Editorial policy: https://healthcarenews.io/editorial-policy/

CAMBRIDGE, Mass., Nov. 12, 2026 [(GLOBE NEWSWIRE)](https://www.globenewswire.com) -- <a href="https://www.globenewswire.com/Tracker?data=c2xWVRhVHrI_LUFhwxzsrFV4WCin85PebUy3zbI-HMrqA5pQGymP0wqf4kn4Tt04sQndwBfxBKWr28DUvWorQ_vcY-2qlsgxlx0-kHMcX2E=" rel="nofollow">Black Diamond Therapeutics, Inc.</a> (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, including silevertinib, a potential best-in-class brain-penetrant epidermal growth factor receptor (EGFR) inhibitor, today announced its participation in upcoming investor conferences. Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D., are as follows:

-   Jefferies Global Healthcare Conference in London presentation at 8:30am GMT / 3:30am ET on Thursday, November 19, 2026
-   9th Annual Evercore ISI Healthcare Conference presentation at 10:25am ET on Tuesday, December 1, 2026
-   Piper Sandler 38th Annual Healthcare Conference presentation at 12:00pm ET on Wednesday, December 2, 2026  
      
    

Webcasts will be available at the start of the presentations on the investor relations section of the Company’s website, <a href="https://www.globenewswire.com/Tracker?data=ZwzHu1jzjLlO9HU00jOADyioGNNe_Xe44uIjgFCgTVNNZxoLZTa7_8JGUr1kHBhoWiBEh-g5RqqTw0DYwjOTq5zf4IdwWOfNHbQ0d_ZDhAYXS5PWxORDLm4lXxq015LO8PLGq2xCPvxCnjvCs2PHCg==" rel="nofollow">www.blackdiamondtherapeutics.com</a>. Replays of the presentations will also be available and archived on the site for 90 days.

**About Silevertinib**

Silevertinib is an investigational oral, covalent, brain-penetrant fourth-generation tyrosine kinase inhibitor (TKI) that selectively targets classical and more than 50 non-classical EGFR mutations in NSCLC. It is also designed to potently inhibit key EGFR alterations seen in GBM. To date, over 200 patients with EGFRm NSCLC or EGFR-altered GBM have been treated with silevertinib.

Based on feedback from the U.S. Food and Drug Administration (FDA) at an End-of-Phase 2 meeting in Q4 2026, the Company is planning to initiate a Phase 3 trial in Q2 2027 in 1L EGFRm NSCLC patients. The Company is also conducting a randomized Phase 2 trial of silevertinib in patients with newly diagnosed EGFRvIII-positive GBM (NCT07326566).

**About Black Diamond Therapeutics**

Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing silevertinib, an investigational brain-penetrant fourth-generation EGFR MasterKey inhibitor targeting EGFR-mutant NSCLC and GBM. For more information, please visit www.blackdiamondtherapeutics.com.

**Contacts**

For Investors:  
<a href="https://www.globenewswire.com/Tracker?data=YzE7P69FC11tG6DadktQKC07k4gxgmJt4lPpoFhRZMTnbSv5KwpI4eGCcFT8RBgjW19qC8NkK9dgo0-69MySOGmk8rHQ8v-Ff_v3VUBJJ7XFZgrdW8rTszaQvhdk8tDc1Im0r7DahTLCfo7zXMWRjSvADbXKdCchiRvohJ6vqDQNp7-z_augdd7xK4x1DSUca0YA8Dy3Puw--NDvAPCIMF41wA-JxPE2azBkvZJ_gsvkWtlveZu1szTPH_80oqkWpMgkWDeaeU7NSwvTNTXnMA==" rel="nofollow">investors@bdtx.com</a>

For Media:  
<a href="https://www.globenewswire.com/Tracker?data=MXbJk3XQ0hJ0aU9ASaU9f19L71t2uOI6aao8POk9Fv7PDb0QQArWb8UuSyX6Vxp3g_9P2vgqyr4MyuEHUMgxww==" rel="nofollow">media@bdtx.com</a>

  
![](https://ml.globenewswire.com/media/Y2MyMmRlZDItZWZjNy00Mjk0LTg2ZDUtYmY4NTcxNTE4MTgyLTEyMDE2MTEtMjAyNi0xMS0xMi1lbg==/tiny/Black-Diamond-Therapeutics-Inc.png)

## Related

- [CapsoVision Reports Third Quarter 2026 Financial Results](https://healthcarenews.io/news/capsovision-reports-third-quarter-2026-financial-results.md)
- [ADARx Reports Third Quarter 2026 Financial Results and Provides Business Updates](https://healthcarenews.io/news/adarx-reports-third-quarter-2026-financial-results-and-provides-business-updates.md)
- [4DMT Reports Third Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones](https://healthcarenews.io/news/4dmt-reports-third-quarter-2026-financial-results-operational-highlights-and-expected-upco.md)
- [Electra Therapeutics Reports Third Quarter 2026 Financial Results and Recent Portfolio Highlights](https://healthcarenews.io/news/electra-therapeutics-reports-third-quarter-2026-financial-results-and-recent-portfolio-hig.md)